Literature DB >> 24518095

Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer.

Shengxiang Ren1, Fred R Hirsch, Marileila Varella-Garcia, Dara L Aisner, Theresa Boyle, Caicun Zhou, D Ross Camidge.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24518095      PMCID： PMC4117236          DOI： 10.1097/JTO.0000000000000013

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  5 in total

1.  Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas.

Authors:  Akihiko Yoshida; Koji Tsuta; Hiroaki Nitta; Yutaka Hatanaka; Hisao Asamura; Ikuo Sekine; Thomas M Grogan; Masashi Fukayama; Tatsuhiro Shibata; Koh Furuta; Takashi Kohno; Hitoshi Tsuda
Journal:  J Thorac Oncol       Date:  2011-10       Impact factor: 15.609

2.  Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer.

Authors:  Nir Peled; Gary Palmer; Fred R Hirsch; Murry W Wynes; Maya Ilouze; Marileila Varella-Garcia; Lior Soussan-Gutman; Geoff A Otto; Philip J Stephens; Jeffrey S Ross; Maureen T Cronin; Doron Lipson; Vincent A Miller
Journal:  J Thorac Oncol       Date:  2012-09       Impact factor: 15.609

3.  Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

Authors:  D Ross Camidge; Scott A Kono; Antonella Flacco; Aik-Choon Tan; Robert C Doebele; Qing Zhou; Lucio Crino; Wilbur A Franklin; Marileila Varella-Garcia
Journal:  Clin Cancer Res       Date:  2010-11-09       Impact factor: 12.531

Review 4.  Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer.

Authors:  Andrew J Weickhardt; Dara L Aisner; Wilbur A Franklin; Marileila Varella-Garcia; Robert C Doebele; D Ross Camidge
Journal:  Cancer       Date:  2012-12-20       Impact factor: 6.860

5.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Authors:  D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw
Journal:  Lancet Oncol       Date:  2012-09-04       Impact factor: 41.316
  5 in total
  18 in total

Review 1.  ALK alterations and inhibition in lung cancer.

Authors:  Tri Le; David E Gerber
Journal:  Semin Cancer Biol       Date:  2016-09-13       Impact factor: 15.707

Review 2.  Tackling ALK in non-small cell lung cancer: the role of novel inhibitors.

Authors:  Francesco Facchinetti; Marcello Tiseo; Massimo Di Maio; Paolo Graziano; Emilio Bria; Giulio Rossi; Silvia Novello
Journal:  Transl Lung Cancer Res       Date:  2016-06

3.  [Statement of the German Society for Pathology and the working group thoracic oncology of the working group oncology/German Cancer Society on ALK testing in NSCLC: Immunohistochemistry and/or FISH?].

Authors:  M von Laffert; P Schirmacher; A Warth; W Weichert; R Büttner; R M Huber; J Wolf; F Griesinger; M Dietel; C Grohé
Journal:  Pathologe       Date:  2016-03       Impact factor: 1.011

4.  ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization.

Authors:  Andrew S Williams; Wenda Greer; Drew Bethune; Kenneth J Craddock; Gordon Flowerdew; Zhaolin Xu
Journal:  Virchows Arch       Date:  2016-08-25       Impact factor: 4.064

5.  ALK detection in lung cancer: identification of atypical and cryptic ALK rearrangements using an optimal algorithm.

Authors:  Yuanyuan Liu; Shafei Wu; Xiaohua Shi; Zhiyong Liang; Xuan Zeng
Journal:  J Cancer Res Clin Oncol       Date:  2020-03-03       Impact factor: 4.553

6.  "Companion diagnostics": has their time come and gone?

Authors:  Fred R Hirsch; Paul A Bunn; Roy S Herbst
Journal:  Clin Cancer Res       Date:  2014-07-24       Impact factor: 12.531

7.  High concordance of ALK rearrangement between primary tumor and paired metastatic lymph node in patients with lung adenocarcinoma.

Authors:  Likun Hou; Shengxiang Ren; Bo Su; Liping Zhang; Wei Wu; Wei Zhang; Zhengwei Dong; Yan Huang; Chunyan Wu; Gang Chen
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

8.  Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.

Authors:  Todd Hembrough; Wei-Li Liao; Christopher P Hartley; Patrick C Ma; Vamsidhar Velcheti; Christopher Lanigan; Sheeno Thyparambil; Eunkyung An; Manish Monga; David Krizman; Jon Burrows; Laura J Tafe
Journal:  Clin Chem       Date:  2015-11-19       Impact factor: 8.327

9.  Detection of EML4-ALK in lung adenocarcinoma using pleural effusion with FISH, IHC, and RT-PCR methods.

Authors:  Leilei Liu; Ping Zhan; Xiaodie Zhou; Yong Song; Xiaojun Zhou; Like Yu; Jiandong Wang
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

10.  Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer.

Authors:  Liping Zhang; Hui Yu; Andrzej Badzio; Theresa A Boyle; Hans-Ulrich Schildhaus; Xian Lu; Rafal Dziadziuszko; Jacek Jassem; Marileila Varella-Garcia; Lynn E Heasley; Ashley A Kowalewski; Kim Ellison; Gang Chen; Caicun Zhou; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2015-07       Impact factor: 15.609
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.